시장보고서

상품코드

1464691

바이러스 벡터 및 플라스미드 DNA 제조 시장 : 벡터 유형별, 워크플로우별, 최종 용도별, 치료 분야별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율 및 예측(2024-2032년)

Viral Vector and Plasmid DNA Manufacturing Market, By Vector Type, By Workflow, By Application, By End-use, By Therapeutic Area, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

발행일: 2024년 04월 | 리서치사:

AnalystView Market Insights | 페이지 정보: 영문 345 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

보고서 하이라이트

바이러스 벡터 및 플라스미드 DNA 제조 시장 규모는 2023년 54억 500만 달러로 평가되며 2024년부터 2032년까지 연평균 복합 성장률(CAGR) 19.7%로 확대될 것으로 예상됩니다.

바이러스 벡터 및 플라스미드 DNA 생산 시장 - 시장 역학

세포 기반 연구에 대한 정부 지원 증가로 시장 수요 증가

바이러스 벡터 및 플라스미드 DNA 제조 시장은 바이러스 벡터 제조를 위한 새로운 기술 및 시설 설립에 대한 정부의 자금 지원이 증가함에 따라 전반적인 연구 활동이 활발해지고 세포 기반 연구가 지원됨에 따라 성장할 것으로 예상됩니다. 또한, 시장 확대를 촉진하는 주요 요인은 암 및 심장 이상을 포함한 질병의 유병률 증가, 세포 치료 연구의 활용, 바이러스 벡터 및 플라스미드 DNA 제조 분야의 기술 발전입니다. 예를 들어, 캐나다 정부는 국민 건강 증진을 위해 유전체학 및 재생의료에 투자했습니다. 줄기세포 네트워크의 경쟁적 연구 자금 이니셔티브를 통해 미화 430만 달러를 지원했습니다. 다발성 경화증, 근이영양증, 암, 혈액 질환, 1형 당뇨병, 심장병, 낭포성 섬유증 등 건강 문제를 치료하기 위한 캐나다 전역의 16개 이니셔티브가 이 직접 자금으로 지원받습니다. 재생의료에 중점을 둔 줄기세포 연구 이니셔티브를 시작하려는 보건, 생명공학, 사회과학 분야의 젊은 연구자들을 지원하는 새로운 프로그램도 이번 공모에 선정된 자금 지원 기회 중 하나입니다. 또한, 게놈 캐나다를 통해 10개의 새로운 게놈 연구에 미화 1,600만 달러가 지원되며, 2035년까지 이 투자는 생의학 및 의약품 개발의 혁신에 기여할 것으로 예상됩니다. 또한, 농업, 건강, 환경 분야의 현실적인 문제와 잠재력을 해결하고 직접적으로 응용할 수 있는 사명감 있는 연구도 지원됩니다.

제품 출시 증가는 시장 매출 성장의 잠재적 기회를 제공합니다.

제품 출시 증가는 예측 기간 동안 시장 성장의 잠재적 기회를 제공할 것으로 예상됩니다. 예를 들어, 2023년 3월 Charles River Laboratories International, Inc.의 기성품 pHelper 서비스 도입으로 아데노부수체 바이러스(AAV) 기반 유전자 치료 이니셔티브는 초기 발견부터 상업적 생산까지 보다 효율적으로 관리할 수 있게 되었습니다. 관리할 수 있게 되었습니다. 연구용(RG), 고품질(HQ), 우수의약품제조관리기준(GMP) 등급을 모두 즉시 이용할 수 있습니다.

바이러스 벡터 및 플라스미드 DNA 제조 시장 - 주요 인사이트

리서치 애널리스트의 분석에 따르면, 세계 시장은 예측 기간(2024-2032년) 동안 약 19.7%의 연평균 성장률(CAGR)을 나타낼 것으로 예상됩니다.

벡터 유형별로는 아데노 동반 바이러스(AAV) 부문이 예측 기간 동안 가장 큰 시장 점유율을 차지할 것으로 예상됩니다.

워크플로우별로는 다운스트림 제조가 예측 기간 동안 큰 시장 점유율을 차지할 것으로 예상됩니다.

치료 분야별로 보면, 예측 기간 동안 종양 질환 분야가 두드러진 시장 점유율을 차지할 것으로 예상됩니다.

지역별로는 북미가 2023년 주요 수익원이 될 것입니다.

바이러스 벡터 및 플라스미드 DNA 제조 시장 - 세분화 분석 :

세계 바이러스 벡터 및 플라스미드 DNA 제조 시장은 벡터 유형, 워크플로우, 용도, 최종 용도, 치료 영역 및 지역에 따라 세분화됩니다.

벡터 유형에 따라 바이러스 벡터 및 플라스미드 DNA 제조 시장은 아데노바이러스, 렌티바이러스, 아데노부수체바이러스(AAV), 레트로바이러스, 플라스미드, 박테리오바이러스, 센다이바이러스, 기타(단순포진바이러스(HSV) 등)로 세분화됩니다. 등으로 세분화됩니다. 아데노부수체 바이러스(AAV) 부문은 예측 기간 동안 가장 큰 시장 점유율을 차지할 것으로 예상되며, AAV는 유전자를 원하는 위치로 전달하는 정확도가 매우 높기 때문에 매우 인기가 높고 임상시험에서 빠르게 사용되고 있습니다. 정형외과 및 안과용 유전자 치료제 개발에 대한 임상 연구에서 효능과 효율성이 개선된 것으로 나타났으며, 이는 AAV의 채택이 증가하는 이유입니다.

워크플로우에 따라 바이러스 벡터 및 플라스미드 DNA 제조 산업은 업스트림 제조와 다운스트림 제조로 나뉩니다. 다운스트림 제조 부문은 치료용 최종 제품을 연마하고 정제하는 데 사용되는 매우 복잡한 공정으로 인해 예측 기간 동안 큰 시장 점유율을 차지할 것으로 예상됩니다.

용도에 따라 시장은 안티센스 및 RNAi 치료, 백신 치료, 유전자 치료, 조직공학, 세포치료, 연구용, 기타(바이오센서 등)로 나뉩니다.

최종 용도에 따라 업계는 제약 및 바이오 제약사, 위탁생산기관(CMO), 연구기관, 기타(정부기관 등)로 나뉩니다.

치료 분야에 따라 바이러스 벡터 및 플라스미드 DNA 생산 시장은 신경질환, 감각기관질환, 근골격계질환, 대사질환, 종양질환, 희귀질환, 혈액질환, 면역질환, 기타(생식의학 등)로 나뉩니다. 예측 기간 동안 종양 질환 분야가 두드러진 시장 점유율을 차지할 것으로 예상됩니다. 이 부문의 성장은 전 세계적으로 암의 유병률이 증가하고 있기 때문입니다. 예를 들어, 국제암연구소(IARC)의 최신 추정에 따르면, 2022년에는 2,000만 명이 새롭게 암에 걸리고 970만 명이 암으로 사망할 것으로 예상됩니다. 암 진단을 받은 후 5년 후에도 생존해 있는 사람은 5,350만 명으로 예상되며, 5명 중 1명은 평생 어딘가에서 암에 걸리고, 남성 9명 중 1명, 여성 12명 중 1명은 암으로 세상을 떠날 것으로 예측됩니다. 이처럼 앞서 언급한 통계가 이 분야의 확장을 부추기고 있습니다.

바이러스 벡터 및 플라스미드 DNA 제조 시장 - 지리적 통찰력

지리적으로 이 시장은 북미, 라틴아메리카, 유럽, 아시아태평양, 중동 및 아프리카에 분포되어 있습니다. 이 지역은 비즈니스를 가져 오는 국가에 따라 더 세분화됩니다. 예측 기간 동안 북미가 가장 큰 시장 점유율을 차지할 것으로 예상됩니다. 이는 이 지역의 개발 수탁 기관 증가와 유전자 및 세포 치료 연구 및 제품 개발에 대한 기업의 참여 증가로 설명할 수 있습니다. 또한, 지역 기업들은 이 지역에 생산 공장을 늘리고 있으며, GMP 제조 서비스를 제공하는 CDMO와 같은 중요한 시장 진출기업들이 존재하고, 제조에 독창적인 제조 방법이 사용됨에 따라 미국은 바이러스 벡터 및 플라스미드 DNA 제조 분야에서 북미 시장에서 가장 큰 매출 점유율을 차지하고 있습니다. 차지하고 있습니다.

바이러스 벡터 및 플라스미드 DNA 생산 시장 - 경쟁 구도:

일부 대기업들은 시장 지위를 향상시키고 고객에게 다양한 서비스를 제공하기 위해 전략적 노력을 기울이고 있습니다. 시장 입지와 수익을 높이고 경쟁력을 확보하기 위해 기업은 파트너십, 계약, 합작 투자, 사업 확장, 서비스 출시, 제품 혁신 및 시장 성장을 가속하는 기타 전술에 자주 참여하고 있습니다. 최근 몇 년동안 플라스미드 DNA 및 바이러스 벡터 시장에서는 주목할 만한 수준의 기술 혁신이 이루어지고 있습니다. 플라스미드 DNA 및 바이러스 벡터 생산업체들은 유전자 치료 및 백신 개발 강화에 대한 수요 증가에 대응하기 위해 끊임없이 새롭고 효과적인 솔루션을 모색하고 있습니다. 바이러스 벡터의 대규모 생산에 일시적 전달 기술을 사용하는 것은 이 시장의 주요 발전 중 하나입니다. 바이러스 벡터 생산에 현탁 세포 배양 기술을 사용하는 것도 혁신적인 접근 방식입니다. 대형 생명공학 및 제약회사들은 특허 기술, 지식 및 제조 능력을 활용하기 위해 중소형 벡터 및 플라스미드 DNA 생산 기업을 자주 인수하고 있습니다. 그 결과, 시장 통합이 진행되고 가격 책정 및 시장 점유율에 대한 기존 기업의 영향력이 강화되고 있습니다. 대기업의 인프라와 자원을 활용하면 중소기업은 사업을 확장하고 새로운 시장에 진입할 수 있습니다. 예를 들어, 2022년 2월 Exelid는 머크 KGaA에 약 7억 8,000만 달러에 인수됐습니다. 최종 사용자에게 mRNA의 밸류체인을 따라 완전한 엔드 투 엔드 CDMO 서비스를 제공함으로써 머크의 생명과학 분야 서비스를 더욱 향상시킬 수 있을 것으로 보입니다.

서론
북미
- 개요
- 북미의 주요 제조업체
- 미국
- 캐나다
유럽
- 개요
- 유럽의 주요 제조업체
- 독일
- 이탈리아
- 영국
- 프랑스
- 러시아
- 네덜란드
- 스웨덴
- 폴란드
- 기타
아시아태평양(APAC)
- 개요
- 아시아태평양의 주요 제조업체
- 인도
- 중국
- 일본
- 한국
- 호주
- 태국
- 인도네시아
- 필리핀
- 기타
라틴아메리카
- 개요
- 라틴아메리카의 주요 제조업체
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 기타
중동 및 아프리카
- 개요
- 중동 및 아프리카의 주요 제조업체
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 터키
- 알제리
- 이집트
- 기타

제13장 주요 벤더 분석 - 바이러스 벡터 및 플라스미드 DNA 제조업계

경쟁 대시보드
기업 개요
- CEVEC Pharmaceuticals
- Catalent Biologics
- Cobra Biologics
- Altruist Biotechnology
- NorthX Biologics
- Novartis
- BioReliance(a subsidiary of Merck KGaA)
- Centre for Process Innovation
- Wuxi AppTech
- Charles River Laboratories
- CoJourney
- Esco Aster
- Jiangsu Puxin Biopharmaceutical
- Lonza
- Advanced BioScience Laboratories
- AGC Biologics
- Aldevron
- Biovian
- Celonic
- BioNTech Innovative Manufacturing Service(a subsidiary of BioNTech)
- Oxford BioMedica
- Sanofi
- Thermo Fisher Scientific
- VectorBuilder
- Matica Biotechnology
- Resilience
- Nikon CeLL innovation

제14장 애널리스트의 전방위 전망

LSH 24.05.24

REPORT HIGHLIGHT

Viral Vector and Plasmid DNA Manufacturing Market size was valued at USD 5,405 Million in 2023, expanding at a CAGR of 19.7% from 2024 to 2032.

Viral vectors and plasmid DNA can be employed in gene therapy to treat a wide range of diseases, such as cancer, metabolic issues, cardiac problems, and neurological disorders. As viral vectors are based on baculovirus, herpes simplex viruses, adenoviruses, and other viruses, they are being employed increasingly frequently in vaccine research and the development of novel medications.

Viral Vector and Plasmid DNA Manufacturing Market- Market Dynamics

Increasing government support for cell-based research to propel market demand

The market for Viral Vector and Plasmid DNA Manufacturing is expected to grow as a result of increased government funding for the creation of new technologies and facilities for producing viral vectors, which has increased overall research activity and supported cell-based research. In addition, the main drivers propelling market expansion are the growing prevalence of diseases including cancer and heart abnormalities, the use of cell therapies research, and technological advancements in the field of viral vector & plasmid DNA manufacture. For instance, the Canadian government made investments in genomics and regenerative medicine to promote the health of its citizens. Through the competitive research funding initiative of the Stem Cell Network, $4.3 million was awarded. 16 initiatives from around Canada that aim to treat health issues like multiple sclerosis, muscular dystrophy, cancer, blood diseases, diabetes type 1, heart disease, and cystic fibrosis will be supported by this direct funding. A new program to assist early career researchers in the health, bioengineering, and social sciences who are creating stem cell research initiatives with an emphasis on regenerative medicine was one of the funding opportunities featured in this competition. In addition, $16 million will be provided to ten new genomics studies through Genome Canada. By 2035, this investment will have contributed to the transformation of biomedicine and drug development. It will also support mission-driven research with direct application potential that tackles real-world problems and possibilities in the fields of agriculture, health, and the environment.

Rising product launches offer a potential opportunity for market revenue growth

The increasing product launch is expected to offer a potential opportunity for market growth during the forecast period. For instance, in March 2023, Adeno-associated virus (AAV)-based gene therapy initiatives can now be more efficiently managed from early discovery to commercial manufacture with the introduction of Charles River Laboratories International, Inc.'s off-the-shelf pHelper service. Research Grade (RG), High Quality (HQ), and Good Manufacturing Practice (GMP) grades are all instantly available.

Viral Vector and Plasmid DNA Manufacturing Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 19.7% over the forecast period (2024-2032)

Based on vector type segmentation, the Adeno-Associated Virus (AAV) segment is expected to hold the largest market share over the forecast period

Based on workflow segmentation, the Downstream Manufacturing segment is expected to hold a significant market share over the projected period

Based on the therapeutic area, the oncological disorder segment is expected to hold a prominent market share over the forecast period

Based on region, North America was the leading revenue generator in 2023

Viral Vector and Plasmid DNA Manufacturing Market- Segmentation Analysis:

The Global Viral Vector and Plasmid DNA Manufacturing Market is segmented based on Vector Type, Workflow, Application, End-use, Therapeutic Area, and Region.

Based on the vector type, the Viral Vector and Plasmid DNA Manufacturing market is segmented into Adenovirus, Lentivirus, Adeno-Associated Virus (AAV), Retrovirus, Plasmids, Baculovirus, Sendai Virus and Others (Herpes Simplex Virus (HSV), etc.). The Adeno-Associated Virus (AAV) segment is expected to hold the largest market share over the forecast period. Due to their exceptional precision in delivering the gene to the desired location, AAVs are extremely sought after and are being used in clinical trials at a rapid pace. Clinical investigations about the development of orthopedic and ophthalmic gene therapy medicines are showing enhanced efficacy and efficiency, which is the reason for the increasing adoption.

Based on the workflow, the Viral Vector and Plasmid DNA Manufacturing industry is bifurcated into Upstream Manufacturing and Downstream Manufacturing. The Downstream Manufacturing segment is expected to hold a significant market share over the projected period due to the extremely intricate processes used to polish and purify final products of therapeutic grade.

Based on the application, the market is bifurcated into Antisense & RNAi Therapy, Vaccinology, Gene Therapy, Tissue Engineering, Cell Therapy, Research Applications and Others (Biosensors, etc.).

Based on the end-use, the industry is bifurcated into Pharmaceutical and Biopharmaceutical Companies, Contract Manufacturing Organizations (CMOs, Research Institutes and Others (Government Agencies, etc.).

Based on the therapeutic area, the Viral Vector and Plasmid DNA Manufacturing market is bifurcated into Neurological Disorders, Sensory Disorders, Musculoskeletal Disorders, Metabolic Disorders, Oncological Disorders, Rare Diseases, Blood Disorders, Immunological Disorders and Others (Reproductive Health, etc.). The oncological disorder segment is expected to hold a prominent market share over the forecast period. The segment growth is attributed to the rising prevalence of cancer across the globe. For instance, according to the latest estimates by the International Agency for Research on Cancer (IARC), 20 million new instances of cancer and 9.7 million deaths from the disease are anticipated for 2022. 53.5 million people were predicted to still be alive five years after receiving a cancer diagnosis. One in five people will have cancer at some point in their lives; one in nine men and one in twelve women will pass away from the disease. Thus, the aforementioned statistics propel the segment expansion.

Viral Vector and Plasmid DNA Manufacturing Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to hold the largest market share over the forecast period. This is explained by the increasing number of contract development organizations in the area as well as the increasing involvement of businesses in gene and cell therapy research and product development. Furthermore, regional companies are growing their production plants in the area. Due to the existence of significant market participants, such as CDMOs providing GMP manufacturing services, and the use of highly creative manufacturing methods for production, the United States held the largest revenue share in the North American market for viral vectors and plasmid DNA manufacturing.

Viral Vector and Plasmid DNA Manufacturing Market- Competitive Landscape:

Several major businesses are implementing some strategic efforts to improve their market position and provide a wide range of services to customers. To boost market presence and revenue and obtain a competitive edge, organizations frequently engage in partnerships and agreements, joint ventures, expansion, service launches, product innovation and other tactics that fuel market growth. Recent years have seen a notable level of innovation in the market for plasmid DNA and viral vectors. Producers of plasmid DNA and viral vectors are continuously looking for new and effective solutions to meet the growing demand for enhanced gene therapy and vaccine development. The use of transient transfection technology for the large-scale manufacturing of viral vectors is one of the major developments in this market. Utilizing suspension cell culture techniques to produce viral vectors is another innovative approach. Big biotech and pharmaceutical corporations are buying up smaller vector and plasmid DNA producers more frequently to gain access to their patented technologies, knowledge, and manufacturing capabilities. As a result, there is market consolidation, which increases the power of established players over pricing and market share. By utilizing the infrastructure and resources of larger acquirers, smaller businesses can expand their operations and reach new markets. For instance, in February 2022, Exelead was purchased by Merck KGaA for around USD 780 million. Providing end users with full end-to-end CDMO services along the mRNA value chain would further improve Merck's Life Science offering.

Recent Developments:

In October 2023, AGC Biologics announced the expansion of their German pDNA manufacturing facility. It is anticipated that this will assist the business in shortening the manufacturing lead time.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

CEVEC Pharmaceuticals

Catalent Biologics

Cobra Biologics

Altruist Biotechnology

NorthX Biologics

Novartis

BioReliance (a subsidiary of Merck KGaA)

Centre for Process Innovation

Wuxi AppTech

Charles River Laboratories

CoJourney

Esco Aster

Jiangsu Puxin Biopharmaceutical

Lonza

Advanced BioScience Laboratories

AGC Biologics

Aldevron

Biovian

Celonic

BioNTech Innovative Manufacturing Service (a subsidiary of BioNTech)

Oxford BioMedica

Sanofi

Thermo Fisher Scientific

VectorBuilder

Matica Biotechnology

Resilience

Nikon CeLL innovation

GLOBAL VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE- MARKET ANALYSIS, 2019 - 2032

Adenovirus
Lentivirus
Adeno-Associated Virus (AAV)
Retrovirus
Plasmids
Baculovirus
Sendai Virus
Others (Herpes Simplex Virus (HSV), etc.)

GLOBAL VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW- MARKET ANALYSIS, 2019 - 2032

Upstream Manufacturing
Vector Amplification & Expansion
Vector Recovery/Harvesting
Downstream Manufacturing
Purification
Fill Finish

GLOBAL VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

Antisense & RNAi Therapy
Vaccinology
Gene Therapy
Tissue Engineering
Cell Therapy
Research Applications
Others (Biosensors, etc.)

GLOBAL VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END-USE- MARKET ANALYSIS, 2019 - 2032

Pharmaceutical and Biopharmaceutical Companies
Contract Manufacturing Organizations (CMOs)
Research Institutes
Others (Government Agencies, etc.)

GLOBAL VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY THERAPEUTIC AREA- MARKET ANALYSIS, 2019 - 2032

Neurological Disorders
Sensory Disorders
Musculoskeletal Disorders
Metabolic Disorders
Oncological Disorders
Rare Diseases
Blood Disorders
Immunological Disorders
Others (Reproductive Health, etc.)

GLOBAL VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA

1. Viral Vector and Plasmid DNA Manufacturing Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Viral Vector and Plasmid DNA Manufacturing Market Snippet by Vector Type
- 2.1.2. Viral Vector and Plasmid DNA Manufacturing Market Snippet by Workflow
- 2.1.3. Viral Vector and Plasmid DNA Manufacturing Market Snippet by Application
- 2.1.4. Viral Vector and Plasmid DNA Manufacturing Market Snippet by End-use
- 2.1.5. Viral Vector and Plasmid DNA Manufacturing Market Snippet by Therapeutic Area
- 2.1.6. Viral Vector and Plasmid DNA Manufacturing Market Snippet by Country
- 2.1.7. Viral Vector and Plasmid DNA Manufacturing Market Snippet by Region
2.2. Competitive Insights

3. Viral Vector and Plasmid DNA Manufacturing Key Market Trends

3.1. Viral Vector and Plasmid DNA Manufacturing Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Viral Vector and Plasmid DNA Manufacturing Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Viral Vector and Plasmid DNA Manufacturing Market Opportunities
3.4. Viral Vector and Plasmid DNA Manufacturing Market Future Trends

4. Viral Vector and Plasmid DNA Manufacturing Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Viral Vector and Plasmid DNA Manufacturing Market: COVID-19 Impact Analysis

5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
- 5.2.1. Top Performing Segments
- 5.2.2. Marginal Growth Segments
- 5.2.3. Top Looser Segments
- 5.2.4. Marginal Loss Segments

6. Viral Vector and Plasmid DNA Manufacturing Market Landscape

6.1. Viral Vector and Plasmid DNA Manufacturing Market Share Analysis, 2023
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Viral Vector and Plasmid DNA Manufacturing Market - By Vector Type

7.1. Overview
- 7.1.1. Segment Share Analysis, By Vector Type, 2023 & 2032 (%)
- 7.1.2. Adenovirus
- 7.1.3. Lentivirus
- 7.1.4. Adeno-Associated Virus (AAV)
- 7.1.5. Retrovirus
- 7.1.6. Plasmids
- 7.1.7. Baculovirus
- 7.1.8. Sendai Virus
- 7.1.9. Others (Herpes Simplex Virus (HSV), etc.)

8. Viral Vector and Plasmid DNA Manufacturing Market - By Workflow

8.1. Overview
- 8.1.1. Segment Share Analysis, By Workflow, 2023 & 2032 (%)
- 8.1.2. Upstream Manufacturing
  - 8.1.2.1. Vector Amplification & Expansion
  - 8.1.2.2. Vector Recovery/Harvesting
- 8.1.3. Downstream Manufacturing
  - 8.1.3.1. Purification
  - 8.1.3.2. Fill Finish

9. Viral Vector and Plasmid DNA Manufacturing Market - By Application

9.1. Overview
- 9.1.1. Segment Share Analysis, By Application, 2023 & 2032 (%)
- 9.1.2. Antisense & RNAi Therapy
- 9.1.3. Vaccinology
- 9.1.4. Gene Therapy
- 9.1.5. Tissue Engineering
- 9.1.6. Cell Therapy
- 9.1.7. Research Applications
- 9.1.8. Others (Biosensors, etc.)

10. Viral Vector and Plasmid DNA Manufacturing Market - By End-use

10.1. Overview
- 10.1.1. Segment Share Analysis, By End-use, 2023 & 2032 (%)
- 10.1.2. Pharmaceutical and Biopharmaceutical Companies
- 10.1.3. Contract Manufacturing Organizations (CMOs)
- 10.1.4. Research Institutes
- 10.1.5. Others (Government Agencies, etc.)

11. Viral Vector and Plasmid DNA Manufacturing Market - By Therapeutic Area

11.1. Overview
- 11.1.1. Segment Share Analysis, By Therapeutic Area, 2023 & 2032 (%)
- 11.1.2. Neurological Disorders
- 11.1.3. Sensory Disorders
- 11.1.4. Musculoskeletal Disorders
- 11.1.5. Metabolic Disorders
- 11.1.6. Oncological Disorders
- 11.1.7. Rare Diseases
- 11.1.8. Blood Disorders
- 11.1.9. Immunological Disorders
- 11.1.10. Others (Reproductive Health, etc.)

12. Viral Vector and Plasmid DNA Manufacturing Market- By Geography

12.1. Introduction
- 12.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
12.2. North America
- 12.2.1. Overview
- 12.2.2. Viral Vector and Plasmid DNA Manufacturing Key Manufacturers in North America
- 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.2.4. North America Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
- 12.2.5. North America Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
- 12.2.6. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 12.2.7. North America Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
- 12.2.8. North America Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 12.2.9. U.S.
  - 12.2.9.1. Overview
  - 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.2.9.3. U.S. Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
  - 12.2.9.4. U.S. Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
  - 12.2.9.5. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.2.9.6. U.S. Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
  - 12.2.9.7. U.S. Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 12.2.10. Canada
  - 12.2.10.1. Overview
  - 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.2.10.3. Canada Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
  - 12.2.10.4. Canada Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
  - 12.2.10.5. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.2.10.6. Canada Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
  - 12.2.10.7. Canada Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.3. Europe
- 12.3.1. Overview
- 12.3.2. Viral Vector and Plasmid DNA Manufacturing Key Manufacturers in Europe
- 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.3.4. Europe Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
- 12.3.5. Europe Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
- 12.3.6. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 12.3.7. Europe Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
- 12.3.8. Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 12.3.9. Germany
  - 12.3.9.1. Overview
  - 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.9.3. Germany Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
  - 12.3.9.4. Germany Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
  - 12.3.9.5. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.3.9.6. Germany Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
  - 12.3.9.7. Germany Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 12.3.10. Italy
  - 12.3.10.1. Overview
  - 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.10.3. Italy Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
  - 12.3.10.4. Italy Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
  - 12.3.10.5. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.3.10.6. Italy Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
  - 12.3.10.7. Italy Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 12.3.11. United Kingdom
  - 12.3.11.1. Overview
  - 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.11.3. United Kingdom Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
  - 12.3.11.4. United Kingdom Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
  - 12.3.11.5. United Kingdom Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.3.11.6. United Kingdom Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
  - 12.3.11.7. United Kingdom Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 12.3.12. France
  - 12.3.12.1. Overview
  - 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.12.3. France Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
  - 12.3.12.4. France Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
  - 12.3.12.5. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.3.12.6. France Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
  - 12.3.12.7. France Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 12.3.13. Russia
  - 12.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.13.2. Russia Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
  - 12.3.13.3. Russia Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
  - 12.3.13.4. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.3.13.5. Russia Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
  - 12.3.13.6. Russia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 12.3.14. Netherlands
  - 12.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.14.2. Netherlands Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
  - 12.3.14.3. Netherlands Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
  - 12.3.14.4. Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.3.14.5. Netherlands Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
  - 12.3.14.6. Netherlands Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 12.3.15. Sweden
  - 12.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.15.2. Sweden Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
  - 12.3.15.3. Sweden Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
  - 12.3.15.4. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.3.15.5. Sweden Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
  - 12.3.15.6. Sweden Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 12.3.16. Poland
  - 12.3.16.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.16.2. Poland Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
  - 12.3.16.3. Poland Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
  - 12.3.16.4. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.3.16.5. Poland Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
  - 12.3.16.6. Poland Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 12.3.17. Rest of Europe
  - 12.3.17.1. Overview
  - 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.17.3. Rest of the Europe Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
  - 12.3.17.4. Rest of the Europe Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
  - 12.3.17.5. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.3.17.6. Rest of the Europe Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
  - 12.3.17.7. Rest of the Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.4. Asia Pacific (APAC)
- 12.4.1. Overview
- 12.4.2. Viral Vector and Plasmid DNA Manufacturing Key Manufacturers in Asia Pacific
- 12.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.4.4. Asia Pacific Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
- 12.4.5. Asia Pacific Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
- 12.4.6. Asia Pacific Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 12.4.7. Asia Pacific Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
- 12.4.8. Asia Pacific Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 12.4.9. India
  - 12.4.9.1. Overview
  - 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.9.3. India Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
  - 12.4.9.4. India Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
  - 12.4.9.5. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.4.9.6. India Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
  - 12.4.9.7. India Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 12.4.10. China
  - 12.4.10.1. Overview
  - 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.10.3. China Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
  - 12.4.10.4. China Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
  - 12.4.10.5. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.4.10.6. China Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
  - 12.4.10.7. China Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 12.4.11. Japan
  - 12.4.11.1. Overview
  - 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.11.3. Japan Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
  - 12.4.11.4. Japan Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
  - 12.4.11.5. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.4.11.6. Japan Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
  - 12.4.11.7. Japan Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 12.4.12. South Korea
  - 12.4.12.1. Overview
  - 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.12.3. South Korea Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
  - 12.4.12.4. South Korea Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
  - 12.4.12.5. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.4.12.6. South Korea Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
  - 12.4.12.7. South Korea Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 12.4.13. Australia
  - 12.4.13.1. Overview
  - 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.13.3. Australia Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
  - 12.4.13.4. Australia Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
  - 12.4.13.5. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.4.13.6. Australia Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
  - 12.4.13.7. Australia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 12.4.14. Thailand
  - 12.4.14.1. Overview
  - 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.14.3. Thailand Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
  - 12.4.14.4. Thailand Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
  - 12.4.14.5. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.4.14.6. Thailand Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
  - 12.4.14.7. Thailand Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 12.4.15. Indonesia
  - 12.4.15.1. Overview
  - 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.15.3. Indonesia Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
  - 12.4.15.4. Indonesia Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
  - 12.4.15.5. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.4.15.6. Indonesia Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
  - 12.4.15.7. Indonesia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 12.4.16. Philippines
  - 12.4.16.1. Overview
  - 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.16.3. Philippines Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
  - 12.4.16.4. Philippines Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
  - 12.4.16.5. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.4.16.6. Philippines Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
  - 12.4.16.7. Philippines Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 12.4.17. Rest of APAC
  - 12.4.17.1. Overview
  - 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.17.3. Rest of APAC Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
  - 12.4.17.4. Rest of APAC Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
  - 12.4.17.5. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.4.17.6. Rest of APAC Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
  - 12.4.17.7. Rest of APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.5. Latin America
- 12.5.1. Overview
- 12.5.2. Viral Vector and Plasmid DNA Manufacturing Key Manufacturers in Latin America
- 12.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.5.4. Latin America Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
- 12.5.5. Latin America Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
- 12.5.6. Latin America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 12.5.7. Latin America Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
- 12.5.8. Latin America Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 12.5.9. Brazil
  - 12.5.9.1. Overview
  - 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.9.3. Brazil Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
  - 12.5.9.4. Brazil Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
  - 12.5.9.5. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.5.9.6. Brazil Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
  - 12.5.9.7. Brazil Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 12.5.10. Mexico
  - 12.5.10.1. Overview
  - 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.10.3. Mexico Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
  - 12.5.10.4. Mexico Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
  - 12.5.10.5. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.5.10.6. Mexico Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
  - 12.5.10.7. Mexico Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 12.5.11. Argentina
  - 12.5.11.1. Overview
  - 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.11.3. Argentina Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
  - 12.5.11.4. Argentina Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
  - 12.5.11.5. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.5.11.6. Argentina Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
  - 12.5.11.7. Argentina Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 12.5.12. Colombia
  - 12.5.12.1. Overview
  - 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.12.3. Colombia Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
  - 12.5.12.4. Colombia Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
  - 12.5.12.5. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.5.12.6. Colombia Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
  - 12.5.12.7. Colombia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 12.5.13. Rest of LATAM
  - 12.5.13.1. Overview
  - 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.13.3. Rest of LATAM Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
  - 12.5.13.4. Rest of LATAM Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
  - 12.5.13.5. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.5.13.6. Rest of LATAM Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
  - 12.5.13.7. Rest of LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.6. Middle East and Africa
- 12.6.1. Overview
- 12.6.2. Viral Vector and Plasmid DNA Manufacturing Key Manufacturers in Middle East and Africa
- 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.6.4. Middle East and Africa Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
- 12.6.5. Middle East and Africa Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
- 12.6.6. Middle East and Africa Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 12.6.7. Middle East and Africa Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
- 12.6.8. Middle East and Africa Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 12.6.9. Saudi Arabia
  - 12.6.9.1. Overview
  - 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.9.3. Saudi Arabia Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
  - 12.6.9.4. Saudi Arabia Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
  - 12.6.9.5. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.6.9.6. Saudi Arabia Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
  - 12.6.9.7. Saudi Arabia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 12.6.10. United Arab Emirates
  - 12.6.10.1. Overview
  - 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.10.3. United Arab Emirates Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
  - 12.6.10.4. United Arab Emirates Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
  - 12.6.10.5. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.6.10.6. United Arab Emirates Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
  - 12.6.10.7. United Arab Emirates Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 12.6.11. Israel
  - 12.6.11.1. Overview
  - 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.11.3. Israel Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
  - 12.6.11.4. Israel Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
  - 12.6.11.5. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.6.11.6. Israel Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
  - 12.6.11.7. Israel Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 12.6.12. Turkey
  - 12.6.12.1. Overview
  - 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.12.3. Turkey Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
  - 12.6.12.4. Turkey Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
  - 12.6.12.5. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.6.12.6. Turkey Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
  - 12.6.12.7. Turkey Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 12.6.13. Algeria
  - 12.6.13.1. Overview
  - 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.13.3. Algeria Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
  - 12.6.13.4. Algeria Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
  - 12.6.13.5. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.6.13.6. Algeria Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
  - 12.6.13.7. Algeria Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 12.6.14. Egypt
  - 12.6.14.1. Overview
  - 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.14.3. Egypt Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
  - 12.6.14.4. Egypt Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
  - 12.6.14.5. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.6.14.6. Egypt Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
  - 12.6.14.7. Egypt Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 12.6.15. Rest of MEA
  - 12.6.15.1. Overview
  - 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.15.3. Rest of MEA Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
  - 12.6.15.4. Rest of MEA Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
  - 12.6.15.5. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.6.15.6. Rest of MEA Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
  - 12.6.15.7. Rest of MEA Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Viral Vector and Plasmid DNA Manufacturing Industry

13.1. Competitive Dashboard
13.2. Company Profiles
- 13.2.1. CEVEC Pharmaceuticals
- 13.2.2. Catalent Biologics
- 13.2.3. Cobra Biologics
- 13.2.4. Altruist Biotechnology
- 13.2.5. NorthX Biologics
- 13.2.6. Novartis
- 13.2.7. BioReliance (a subsidiary of Merck KGaA)
- 13.2.8. Centre for Process Innovation
- 13.2.9. Wuxi AppTech
- 13.2.10. Charles River Laboratories
- 13.2.11. CoJourney
- 13.2.12. Esco Aster
- 13.2.13. Jiangsu Puxin Biopharmaceutical
- 13.2.14. Lonza
- 13.2.15. Advanced BioScience Laboratories
- 13.2.16. AGC Biologics
- 13.2.17. Aldevron
- 13.2.18. Biovian
- 13.2.19. Celonic
- 13.2.20. BioNTech Innovative Manufacturing Service (a subsidiary of BioNTech)
- 13.2.21. Oxford BioMedica
- 13.2.22. Sanofi
- 13.2.23. Thermo Fisher Scientific
- 13.2.24. VectorBuilder
- 13.2.25. Matica Biotechnology
- 13.2.26. Resilience
- 13.2.27. Nikon CeLL innovation

14. 360 Degree Analyst View

15. Appendix

15.1. Research Methodology
15.2. References
15.3. Abbreviations
15.4. Disclaimer
15.5. Contact Us